2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Vascular Diseases
1
Respiratory Tract Diseases
1
Pulmonary Embolism
1
Neoplasms
1
Lung Diseases
1
Embolism and Thrombosis
1
Embolism
1
Disease
1
Cardiovascular Diseases
1
Interventions
Exercise
440
Blood Specimen Collection
335
Standard of Care
325
Magnetic Resonance Spectroscopy
260
Radiotherapy
255
Surveys and Questionnaires
245
Radiosurgery
245
Methods
231
Educational Status
231
Early Intervention, Educational
219
Interviews as Topic
149
Practice Guidelines as Topic
147
Biopsy
146
Surgical Procedures, Operative
136
Drug Therapy
133
Control Groups
128
Acupuncture Therapy
124
Therapeutics
110
Cyclophosphamide
103
Palliative Care
101
Counseling
101
Resistance Training
96
Saline Solution
90
Cisplatin
90
Magnetic Resonance Imaging
89
Radiofrequency Ablation
86
Specimen Handling
83
Radiotherapy, Intensity-Modulated
79
Colonoscopy
79
Cognitive Behavioral Therapy
72
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase NA
×
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid
×
Clear all
NCT04657120
2025-12-23
HYDRA
Leiden University Medical Center
Phase NA
Completed
698 enrolled